Lung Cancer Treatment for Never Smokers: The HARMONIC Phase 2 Trial and LP-300

Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma, discussed 'Breakthroughs in Lung Cancer Treatment for Never Smokers,' including the novel AI-assisted drug candidate, LP-300 in this exclusive interview. He delved into the promising results of the HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating lung cancer.

Additionally, we explore the transformative role of artificial intelligence in drug discovery, particularly how it's reshaping clinical trials and treatment strategies.

Some of the main topics in this interview include:

• Smoking has traditionally been recognized as a major risk factor for lung cancer. However, there's a growing group of lung cancer patients who have never smoked, presenting new challenges for treatment.
• In the HARMONIC™ Phase 2 trial, you've reported an 86% clinical benefit rate in the initial patient cohort for LP-300, and the objective response rate stands at 43% with notable reductions in tumor sizes. How do these results compare to existing treatments and what is their potential impact on future clinical practice?
• How does LP-300's mechanism of action interact with tyrosine kinase inhibitors and affect cancer cells in never smokers?
• What will the impact of your findings from the HARMONIC™ trial be on the future treatment of lung cancer?
• Were there any safety concerns observed during the trial, and how do these compare to typical treatments?
• As AI continues to play a crucial role in drug development, what is the future integration of AI and machine learning in clinical practice, particularly for oncologists? What are the next steps?